Alnylam Pharmaceuticals, Inc. (ALNY)
NASDAQ: ALNY · Real-Time Price · USD
165.04
+8.39 (5.36%)
At close: Nov 13, 2026, 4:00 PM EST
165.91
+0.87 (0.53%)
After-hours: Nov 13, 2026, 7:59 PM EST
Alnylam Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 5,013 | 3,714 | 2,248 | 1,828 | 1,037 | 844.29 | |
Revenue Growth | 56.17% | 65.19% | 22.97% | 76.23% | 22.88% | 71.31% |
Cost of Revenue | 1,139 | 681.87 | 323.37 | 310.41 | 168.82 | 140.14 |
Gross Profit | 3,874 | 3,032 | 1,925 | 1,518 | 868.6 | 704.14 |
Selling, General & Admin | 1,338 | 1,211 | 975.53 | 795.65 | 770.66 | 620.64 |
Research & Development | 1,559 | 1,320 | 1,126 | 1,004 | 883.02 | 792.16 |
Operating Expenses | 2,897 | 2,530 | 2,102 | 1,800 | 1,654 | 1,413 |
Operating Income | 977.59 | 501.58 | -176.89 | -282.18 | -785.07 | -708.65 |
Interest Expense | -301.11 | -252.63 | -141.86 | -121.22 | -155.97 | -143.02 |
Interest & Investment Income | 112.31 | 111.47 | 121.99 | 95.56 | 24.81 | 1.58 |
Other Non Operating Income (Expenses) | -46.41 | -34.96 | -177.6 | -108.74 | -100.86 | -57.75 |
EBT Excluding Unusual Items | 742.38 | 325.46 | -374.35 | -416.57 | -1,017 | -907.84 |
Gain (Loss) on Sale of Investments | - | -2.31 | -3.02 | -16.94 | -33.31 | 55.7 |
Other Unusual Items | 39.15 | - | - | - | -76.59 | - |
Pretax Income | 781.53 | 323.15 | -377.38 | -433.52 | -1,127 | -852.14 |
Income Tax Expense | -1,868 | 9.41 | -99.22 | 6.73 | 4.16 | 0.68 |
Net Income | 2,649 | 313.75 | -278.16 | -440.24 | -1,131 | -852.82 |
Net Income to Common | 2,649 | 313.75 | -278.16 | -440.24 | -1,131 | -852.82 |
Net Income Growth | 2136.86% | - | - | - | - | - |
Shares Outstanding (Basic) | 133 | 131 | 128 | 125 | 122 | 118 |
Shares Outstanding (Diluted) | 138 | 135 | 128 | 125 | 122 | 118 |
Shares Change | 3.63% | 5.51% | 2.20% | 2.64% | 2.73% | 3.01% |
EPS (Basic) | 19.90 | 2.39 | -2.18 | -3.52 | -9.30 | -7.20 |
EPS (Diluted) | 19.29 | 2.33 | -2.18 | -3.52 | -9.30 | -7.20 |
EPS Growth | 2056.93% | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 806.31 | 465.38 | -42.59 | 41.95 | -613.33 | -718.07 |
Free Cash Flow Per Share | 5.86 | 3.46 | -0.33 | 0.34 | -5.04 | -6.06 |
Gross Margin | 77.28% | 81.64% | 85.62% | 83.02% | 83.73% | 83.40% |
Operating Margin | 19.50% | 13.51% | -7.87% | -15.43% | -75.68% | -83.94% |
Profit Margin | 52.85% | 8.45% | -12.37% | -24.08% | -109.04% | -101.01% |
Free Cash Flow Margin | 16.08% | 12.53% | -1.89% | 2.29% | -59.12% | -85.05% |
EBITDA | 1,033 | 557.24 | -120.22 | -228.12 | -740.6 | -661.09 |
EBITDA Margin | 20.61% | 15.00% | -5.35% | -12.48% | -71.39% | -78.30% |
D&A For EBITDA | 55.43 | 55.66 | 56.67 | 54.05 | 44.47 | 47.57 |
EBIT | 977.59 | 501.58 | -176.89 | -282.18 | -785.07 | -708.65 |
EBIT Margin | 19.50% | 13.51% | -7.87% | -15.43% | -75.67% | -83.94% |
Effective Tax Rate | - | 2.91% | - | - | - | - |
Revenue as Reported | 5,013 | 3,714 | 2,248 | 1,828 | 1,037 | 844.29 |
Advertising Expenses | - | 36 | 29.7 | 12.4 | 11.7 | - |